Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12 studies found for:    Open Studies | "Rhinitis, Allergic, Seasonal"
Show Display Options
Rank Status Study
1 Recruiting Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis
Condition: Seasonal Allergic Rhinitis
Interventions: Drug: Bifidobacteria;   Drug: placebo
2 Recruiting Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
Condition: Seasonal Allergic Rhinitis (SAR)
Interventions: Drug: GSP 301 NS;   Drug: GOM-NS;   Drug: GMM-2 NS;   Drug: GSP 301 placebo NS
3 Recruiting Intralymphatic Immunotherapy in Increasing Doses, Substudy
Condition: Rhinitis, Allergic, Seasonal
Interventions: Drug: ALK Diluent;   Drug: ALK Alutard SQ 5-grasses or ALK Alutard Birch
4 Recruiting Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
Condition: Rhinitis, Allergic, Seasonal
Interventions: Biological: MK-3641;   Biological: Placebo;   Drug: Self-injectable epinephrine;   Drug: Albuterol/Salbutamol;   Drug: Loratadine;   Drug: Olopatadine;   Drug: Mometasone furoate monohydrate
5 Recruiting Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
Condition: Hay Fever
Interventions: Biological: Placebo solution;   Biological: gpASIT+TM
6 Recruiting Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: Placebo;   Drug: Fluticasone propionate;   Drug: Fluticasone/Azelastine nasal spray;   Procedure: Nasal Allergen Challenge
7 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MG56 Mannosylated 5.000 subcutaneous;   Biological: MG56 Mannosylated 10.000 subcutaneous;   Biological: MG56 Mannosylated 30.000 subcutaneous;   Biological: MG56 Mannosylated 50.000 subcutaneous;   Biological: MG56 Mannosylated 5.000 sublingual;   Biological: MG56 Mannosylated 10.000 sublingual;   Biological: MG56 Mannosylated 30.000 sublingual;   Biological: MG56 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
8 Not yet recruiting A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
Conditions: Allergic Rhinitis;   Allergic Conjunctivitis
Interventions: Biological: modified allergen extract;   Biological: Placebo
9 Not yet recruiting Efficacy and Safety of Sublingual Immunotherapy (SLIT)
Condition: Allergic Rhinitis
Interventions: Biological: sublingual immunotherapy with allergen extract;   Biological: sublingual immunotherapy with placebo
10 Not yet recruiting Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Conditions: Lung Transplant;   Lung Resection;   Lung Cancer;   Asthma;   Cystic Fibrosis;   Chronic Obstructive Pulmonary Disease;   Emphysema;   Mesothelioma;   Asbestosis;   Pulmonary Embolism;   Interstitial Lung Disease;   Pulmonary Fibrosis;   Bronchiectasis;   Seasonal Allergies;   Cold Virus;   Lung Infection;   Pulmonary Hypertension;   Pulmonary Dysplasia;   Obstructive Sleep Apnea
Interventions: Drug: HP 3He;   Drug: HP 129Xe;   Drug: PFP;   Drug: SF6;   Device: 129Xe Small and Large Human Lung Coil;   Device: 3He Human Lung Coil;   Device: PFP and SF6 Human Lung Coil
11 Recruiting Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response
Condition: Hypersensitivity
Interventions: Biological: BM32;   Biological: Placebo
12 Recruiting Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
Conditions: Allergic Rhinitis;   Asthma;   Latent Tuberculosis
Interventions: Other: TLR Agonist;   Other: Tuberculin nasal challenge;   Other: Timothy Grass Pollen

Study has passed its completion date and status has not been verified in more than two years.